Hims & Hers Health (NYSE:HIMS) Given “Neutral” Rating at Piper Sandler

Piper Sandler restated their neutral rating on shares of Hims & Hers Health (NYSE:HIMS) in a report issued on Tuesday, Benzinga reports. The brokerage currently has a $18.00 target price on the stock.

HIMS has been the topic of several other research reports. Truist Financial lifted their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a hold rating in a research note on Thursday, July 18th. Jefferies Financial Group increased their price objective on shares of Hims & Hers Health from $14.00 to $23.00 and gave the company a hold rating in a report on Thursday, June 27th. Deutsche Bank Aktiengesellschaft boosted their target price on Hims & Hers Health from $14.00 to $16.00 and gave the stock a hold rating in a report on Tuesday, May 7th. Canaccord Genuity Group increased their price target on Hims & Hers Health from $20.00 to $24.00 and gave the company a buy rating in a report on Wednesday, May 22nd. Finally, TD Cowen boosted their price objective on Hims & Hers Health from $15.00 to $25.00 and gave the stock a buy rating in a research note on Thursday, July 11th. Eight research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of Hold and a consensus price target of $20.00.

Hims & Hers Health Stock Up 0.7 %

Shares of HIMS stock traded up $0.11 during mid-day trading on Tuesday, hitting $15.96. 8,244,545 shares of the stock were exchanged, compared to its average volume of 7,900,966. Hims & Hers Health has a 52-week low of $5.65 and a 52-week high of $25.74. The company has a market cap of $3.43 billion, a PE ratio of -1,596.00 and a beta of 1.08. The firm has a fifty day moving average of $21.12 and a 200 day moving average of $15.91.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The firm had revenue of $315.65 million for the quarter, compared to analyst estimates of $302.43 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The business’s revenue was up 51.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.03) EPS. Equities analysts predict that Hims & Hers Health will post 0.2 EPS for the current year.

Insiders Place Their Bets

In related news, COO Melissa Baird sold 16,784 shares of the business’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $17.00, for a total transaction of $285,328.00. Following the completion of the transaction, the chief operating officer now directly owns 585,800 shares of the company’s stock, valued at approximately $9,958,600. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, COO Melissa Baird sold 16,784 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $17.00, for a total value of $285,328.00. Following the completion of the transaction, the chief operating officer now owns 585,800 shares in the company, valued at $9,958,600. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Soleil Boughton sold 2,334 shares of the stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $17.30, for a total transaction of $40,378.20. Following the completion of the sale, the insider now directly owns 164,475 shares in the company, valued at $2,845,417.50. The disclosure for this sale can be found here. Insiders have sold a total of 980,907 shares of company stock worth $19,445,689 in the last ninety days. 17.71% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC lifted its position in Hims & Hers Health by 103.2% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 43,662 shares of the company’s stock valued at $389,000 after acquiring an additional 22,170 shares during the last quarter. Custom Index Systems LLC acquired a new stake in shares of Hims & Hers Health in the 4th quarter valued at about $132,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Hims & Hers Health by 5.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock worth $261,000 after buying an additional 1,561 shares during the last quarter. Russell Investments Group Ltd. increased its position in Hims & Hers Health by 30.7% during the fourth quarter. Russell Investments Group Ltd. now owns 167,328 shares of the company’s stock worth $1,489,000 after buying an additional 39,337 shares during the period. Finally, Certuity LLC purchased a new stake in Hims & Hers Health in the fourth quarter valued at approximately $109,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.